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Methods: Among 33 naïve chronic hepatitis B patients, the
serum level Changes of sCD26 and sCD30 before, 1 and
3 months after the start of therapy with IFNa were evaluated
using sandwich enzyme-linked immonosorbant assay. The
success Rate of treatment with IFNa was also obtained in
these patients.
Result: sCD26 serum level changes before the start of
therapy till one month (P= 0.001) and three months
(P< 0.001) after the start of therapy were related to success
rate of therapy. sCD30 serum level changes were not related
to treatment success.
Conclusion: Using changes of serum level of sCD26 might
be useful in predicting the outcome of therapy in naïve
chronic hepatitis B patients undergoing treatment with
IFNa. More studies with longer follow up time in this topic
are recommended.
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Background: Kupffer cells and related cytokines are
believed to play a critical role in liver ﬁbrosis. However,
it is not clear what role Kupffer cells play in HBV-related
ﬁbrogenesis.
Methods: Primary rat Kupffer cells were cultured with
different titers of HBV particles puriﬁed from the sera
of chronic hepatitis B patients. The concentrations of
TGF-b1, IL-6, IL-1 and TNF-a in the culture supernatant
were measured every 24 hours for 7 days. The mRNA and
protein levels of these cytokine in Kupffer cells were also
analyzed by quantitative real-time PCR and Western blot,
respectively.
Results: Kupffer cells maintained normal morphology and
function throughout the 7-day HBV treatment. TGF-b1
secreted by Kupffer cells under stimulation with HBV at
6 Log IU mL 1 increased 5.38±4.54- and 7.75±4.27-fold
by Days 3 and 7, respectively (p < 0.01). Western blotting
showed the expression of TGF-b1 in Kupffer cells exposed
to high titer HBV increased from 1.80±0.20- to 2.42±0.46-
fold by Days 3 and 7, respectively (p < 0.01). In contrast,
Kupffer cell expression and secretion of proinﬂammatory
cytokines (IL-6, IL-1 and TNF-a) were unchanged throughout
the experiment.
Conclusion: HBV could preferably stimulate Kupffer cells
to produce proﬁbrogenic/anti-inﬂammtory cytokine TGF-b1
over proinﬂammatory cytokines IL-6, IL-1 and TNF-a. This in
vitro study may partly explain why overt liver ﬁbrosis still
presents in chronic HBV infection with minimal or even in
the absence of necroinﬂammation.
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Background: Spontaneous decrease of HBV DNA among
chronic hepatitis B (CHB) patients who were not treated
with antivirus drugs had been reported. The aim of this
study was to compare the HBV DNA change between HBeAg
positive and negative CHB patients.
Methods: Dynamic change of HBV DNA level was observed
for 12 weeks in 171 cases with admission HBV DNA level
above 10,000 copies/mL. All patients had never been
treated with antiviral or immunoregulatory drugs during
this period. HBV DNA detection were carried out every two
weeks. HBV DNA baselines, minimum level and changing
degree of HBV DNA were compared respectively between
the two groups. All the data were analyzed by software
SPSS 13.0, t-test was used to compare means and difference
was signiﬁcant statistically when P < 0.05.
Results: Among HBeAg positive patients (n = 83, 48.5%),
HBV DNA baseline, minimum level and changing degree
of HBV DNA were (7.44±1.32) copies/ml, (3.59±0.99)
copies/ml and (3.84±1.39) copies/ml, respectively; Among
HBeAg negative patients (n = 88, 51.5%), HBV DNA
baseline, minimum level and changing degree of HBV
DNA were (7.26±0.96) copies/ml, (3.93±1.18) copies/ml,
(3.35±1.070) copies/ml respectively. HBV DNA baselines had
no signiﬁcant difference statistically (t = 0.759, P = 0.449);
minimum level of HBeAg positive patients was lower than
that of HBeAg negative patients (t = 2.020, P = 0.045);
changing degree of HBV DNA of HBeAg positive patients
was greater than that of HBeAg negative patients (t = 2.363,
P = 0.027).
Conclusion: Among patients with chronic hepatitis B
underwent spontaneous HBV DNA decrease, HBeAg positive
patients were more likely to have a greater HBV DNA change
and lower minimum.
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Objective: Liver-APOBEC enzyme mediated G→A
hypermutation has been reported in HBV genome that
prefers 5′GGGG tetrad substrate as an antiviral-innate
immune mechanism. We therefore, intended to analyze the
occurrence of G→A hypermutations in the in the 5′GGGG
tetrad of HBV pre-C coding sequences from HBeAg negative
patients.
Methods: Six HBeAg seronegative hepatitis B patients with
chronic liver disease were studied that fulﬁlled the inclusion
criteria: presence of chronic hepatitis: persistence of HBsAg
and anti-HBeAb seropositivity for at least 12 months, HBV
DNA seropositivity, liver ALT level >1.5× upper limit of
normal, and seronegativity for HCV and HDV. Viral DNA
were extracted from the patient’s sea and subjected to PCR-
ampliﬁcation, using pre-C/C speciﬁc primer sets followed by
direct automated sequencing. The nucleotide sequences of
HBe negative HBV variants were analyzed with that of wild
type HBV, using the on line DNA multi-alignment program.
Results: The pre-C nucleotide sequence analysis of the
six HBe negative viral variants showed classical G1896A
mutations in 3 samples. Of these, one viral sequence
showed an additional G1897A substitution, representing
a ‘dinucleotide-pattern’ hypermutation resulting in pre-C
stop codon (UGG→UAA) in the 5′GGGG tetrad. In another
sample, a second G1899A substitution was also identiﬁed in
the same tetrad stetch, but in the next codon (UGGGGC→
UAGGAC).
Conclusion(s): (1) The pre-C 5′GGGG stretch appears as a
hot-spot for G→A stop codon-mutations in the HBe negative
chronic hepatitis B patients, and (2) This ‘dinucleotide-
pattern’ G→A hypermutation are likely to be introduced by
the host-APOBEC enzymes.
